NCT06783049 Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack With an Intelligent Management System
| NCT ID | NCT06783049 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 4,490 participants |
| Start Date | 2025-03-03 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 4,490 participants in total. It began in 2025-03-03 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to develop a digital health-based intelligent management system for the secondary prevention of ischemic stroke and to evaluate its effectiveness through a multicenter randomized controlled trial, assessing its health economic value. Participants will receive usual care after discharge (control group) or be managed with a WeChat-based intelligent management system after discharge (intervention group). At one year, all patients will undergo face-to-face follow-up to assess clinical events, medication adherence, and the achievement of target risk factor levels.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years. 2. Patients diagnosed with acute ischemic stroke or transient ischemic attack. 3. Time from onset to enrollment ≤ 14 days. 4. Presence of at least one modifiable risk factor (hypertension, diabetes). 5. Ability to independently use a smartphone to complete system tasks upon discharge, or with the assistance of family members. 6. Signed informed consent by the patient or their family members. Exclusion Criteria: 1. Patients already enrolled in other stroke-related healthcare quality improvement projects or clinical trials. 2. Patients or family members who refuse to sign the informed consent form. 3. Pregnant or breastfeeding women.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06783049 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06783049 currently recruiting?
Yes, NCT06783049 is actively recruiting participants. Contact the research team at fzyhhz1996@gmail.com for enrollment information.
Where is the NCT06783049 trial being conducted?
This trial is being conducted at Beijing, China, Shihezi, China, Beijing, China.
Who is sponsoring the NCT06783049 clinical trial?
NCT06783049 is sponsored by Beijing Tiantan Hospital. The trial plans to enroll 4,490 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.